Response Genetics, Inc.(RGDX)- NASDAQ
  • Aug. 10, 2015, 10:13 AM
    • Cancer Genetics (CGIX +5.2%) enters into an agreement in principle to act as a "stalking horse" and acquire all the assets and operations of Response Genetics (RGDX -48.7%) for $14M, $7M in cash and $7M in CGIX stock.
    • The deal will add $10M - 12M in revenue to CGI's top line over the next 12 months and more than double its clinical revenue base. As part of the transaction, Response has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court.
    • A "stalking horse" bid under the U.S. Bankruptcy Code means other parties have the opportunity to submit competing offers. CGIX is entitled to a break-up fee and expense reimbursement if it does not prevail in its bid. The acquisition agreement in principle remains subject to finalization within seven days of Response's Chapter 11 filing.
    | Aug. 10, 2015, 10:13 AM | 1 Comment
  • Jul. 6, 2015, 7:21 AM
    • In a regulatory filing, Response Genetics (NASDAQ:RGDX) discloses that, effective today, it will be delisted from the Nasdaq and will begin trading on the OTCQB market. The stock symbol will remain unchanged.
    | Jul. 6, 2015, 7:21 AM
  • May 14, 2015, 8:45 AM
    • Response Genetics (RGDX +6.7%) Q1 results: Revenues: $3.8M (-2.6%); COGS: $2.3M (-4.2%); Opearting Expenses: $5.1M (+4.1%); Operating Loss: ($3.6M) (-2.9%); Net Loss: ($4M) (-14.3%); Loss Per Share: ($0.10) (-11.1%); Quick Assets: $1.7M (-22.7%).
    • No guidance given.
    | May 14, 2015, 8:45 AM
  • May 14, 2015, 7:02 AM
    • Response Genetics (NASDAQ:RGDX): Q1 EPS of -$0.10
    • Revenue of $3.8M (-2.6% Y/Y)
    | May 14, 2015, 7:02 AM
  • Apr. 1, 2015, 6:45 AM
    • Response Genetics (RGDX) Q4 results: Revenues: $4.1M (-14.6%); COGS: $2.4M (-4.0%); R&D Expense: $0.3M (-40.0%); SG&A: $4.4M (-12.0%); Operating Loss: ($3.1M) (+3.1%); Net Loss: ($3.4M) (-6.2%); Loss Per Share: ($0.09) (unch).
    • FY2014 results: Revenues: $16.7M (+70.4%); COGS: $10M (-4.8%); R&D Expense: $1.7M (+6.2%); SG&A: $18M (+14.6%); Operating Loss: ($13M) (-64.6%); Net Loss: ($13.7M) (-71.3%); Loss Per Share: ($0.35) (-45.8%); Quick Assets: $2.2M (-72.8%).
    • No guidance given.
    | Apr. 1, 2015, 6:45 AM
  • Mar. 31, 2015, 4:10 PM
    • Response Genetics (NASDAQ:RGDX): Q4 EPS of -$0.09
    • Revenue of $4.1M (-14.6% Y/Y)
    | Mar. 31, 2015, 4:10 PM
  • Feb. 26, 2015, 1:45 PM
    • Giddy biotech traders continue to spread their enthusiasm around the nano cap space.
    • Thinly-traded Response Genetics (RGDX +26.9%) jumps on a 7x surge in volume. The $26M market cap firm provides diagnostic testing services for various cancers. Revenues for the most recent four quarters: $17.4M.
    • Thinly-traded Cyclacel Pharmaceuticals (CYCC +50%) jumps on a 4.5x spike in volume. The $26M market cap firm develops oral therapies for treatment of cancer. Revenues for the most recent four quarters: $1.8M.
    | Feb. 26, 2015, 1:45 PM | 2 Comments
  • Nov. 13, 2014, 11:49 AM
    • Response Genetics (RGDX -27.1%) Q3 results: Revenues: $4.5M (+9.8%); COGS: $2.5M (-7.4%); Operating Expenses: $5.3M (+29.3%); Operating Loss: ($3.4M) (-25.9%); Net Loss: ($3.6M) (-33.3%); Loss Per Share: ($0.09) (-12.5%); Quick Assets: $6M (-25.9%).
    • No guidance given.
    | Nov. 13, 2014, 11:49 AM
  • Nov. 13, 2014, 7:03 AM
    • Response Genetics (NASDAQ:RGDX): Q3 EPS of -$0.09.
    • Revenue of $4.5M (+9.8% Y/Y).
    | Nov. 13, 2014, 7:03 AM
  • Nov. 6, 2014, 1:38 PM
    • Response Genetics (RGDX +5.9%) will report Q3 results on November 13 before the open. The conference call will begin at 5:30 am PT/8:30 am ET.
    | Nov. 6, 2014, 1:38 PM
  • Aug. 18, 2014, 4:07 PM
    • NCI's Frederick National Laboratory for Cancer Research operations and technical support contractor Leidos Biomedical Research awards the molecular testing contract for ALCHEMIST to Response Genetics (RGDX +3.8%). The contract will run 5 - 6 years and will involve screening thousands of early-stage lung cancer patients for EGFR gene mutations and ALK gene rearrangement.
    • ALCHEMIST consists of three integrated studies (one screening and two treatment) implemented through the National Clinical Trials Network of the National Cancer Institute.
    • The specific monetary size is not disclosed, but is referred to as "multimillion."
    | Aug. 18, 2014, 4:07 PM
  • Aug. 14, 2014, 7:32 AM
    • Response Genetics (NASDAQ:RGDX) Q2 results: Revenues: $5.3M (+24.1%); Operating Expenses: $3.9M (-19.2%); Operating Loss: ($1.3M) (+59.0%); Net Loss: ($1.3M) (+58.7%); Loss Per Share: ($0.04) (+50.0%); Quick Assets: $8.1M (+281.4%).
    • No financial guidance given.
    | Aug. 14, 2014, 7:32 AM | 1 Comment
  • Aug. 14, 2014, 7:07 AM
    • Response Genetics (NASDAQ:RGDX): Q2 EPS of -$0.04.
    • Revenue of $4.3M (-19.0% Y/Y).
    | Aug. 14, 2014, 7:07 AM
  • Aug. 5, 2014, 11:39 AM
    • Response Genetics (RGDX -10.9%) enters into a credit agreement with SWK Funding LLC for a multi-draw term loan for up to $12M. On the closing date of the agreement, July 30, 2014, SWK advanced the company $8.5M which is due on July 30, 2020.
    • Under the terms of the agreement, the loan will bear an interest rate of LIBOR plus 12.5%.
    • SWK also receives a warrant to purchase 681,090 shares of RGDX common stock at $0.936 per share. It may exercise the warrant on a cashless basis at any time. RGDX currently trades at $0.70 per share.
    | Aug. 5, 2014, 11:39 AM | 3 Comments
  • May 8, 2014, 12:48 PM
    | May 8, 2014, 12:48 PM
  • Apr. 4, 2014, 9:10 AM
    | Apr. 4, 2014, 9:10 AM
Company Description
Response Genetics, Inc. engages in the research and development of clinical diagnostic tests for cancer. It has developed technologies for the extraction of Ribonucleic acid (RNA) from formalin-fixed and paraffin-embedded tissues which enables to reliably recover RNA suitable for a variety of... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States